Desmopressin "Newbury" 240 mikrogram resoribletter, sublinguale Denmark - Denmark - Lægemiddelstyrelsen (Danish Medicines Agency)

desmopressin "newbury" 240 mikrogram resoribletter, sublinguale

newbury pharmaceuticals ab - desmopressinacetat - resoribletter, sublinguale - 240 mikrogram

Desmopressin "Newbury" 60 mikrogram resoribletter, sublinguale Denmark - Denmark - Lægemiddelstyrelsen (Danish Medicines Agency)

desmopressin "newbury" 60 mikrogram resoribletter, sublinguale

newbury pharmaceuticals ab - desmopressinacetat - resoribletter, sublinguale - 60 mikrogram

Edistride Kesatuan Eropah - Denmark - EMA (European Medicines Agency)

edistride

astrazeneca ab - dapagliflozin propandiolmonohydrat - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - narkotika anvendt i diabetes - type 2 diabetes mellitusedistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. i tillæg til andre lægemidler til behandling af type 2-diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 og 5. heart failureedistride is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseedistride is indicated in adults for the treatment of chronic kidney disease.

Forxiga Kesatuan Eropah - Denmark - EMA (European Medicines Agency)

forxiga

astrazeneca ab - dapagliflozin propandiolmonohydrat - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - narkotika anvendt i diabetes - type 2 diabetes mellitusforxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. i tillæg til andre lægemidler til behandling af type 2-diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 og 5. heart failureforxiga is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseforxiga is indicated in adults for the treatment of chronic kidney disease.

Velactis Kesatuan Eropah - Denmark - EMA (European Medicines Agency)

velactis

ceva santé animale - cabergolin - prolactine-hæmmere, genito urinary system and sex hormones, andre gynecologicals - til brug i besætningen management program af malkekøer som en støtte i den bratte tørring-off ved at reducere produktionen af mælk, at:reducere mælk lækage ved goldning;reducere risikoen for nye intramammary infektioner i den tørre periode, for at reducere ubehag.

Bioestrovet 250 mikrogram/ml injektionsvæske, opløsning Denmark - Denmark - Lægemiddelstyrelsen (Danish Medicines Agency)

bioestrovet 250 mikrogram/ml injektionsvæske, opløsning

vetoquinol scandinavia ab - cloprostenolnatrium - injektionsvæske, opløsning - 250 mikrogram/ml - kvæg

Dapagliflozin Viatris Kesatuan Eropah - Denmark - EMA (European Medicines Agency)

dapagliflozin viatris

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - narkotika anvendt i diabetes - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 og 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.